News release

Date: 23rd April 2014

New whitepaper from advanced research instrumentation pioneer Oxford Optronix highlights transformative benefits of automated colony counting for life science researchers

Freely available download reveals the potential of intelligence-based imaging systems for advancing the frontiers of cancer research

Abingdon, UK, 23rd April 2014 –  Oxford Optronix, the leading provider of advanced research instrumentation for the clinical medicine and life science industries, today releases a new whitepaper outlining the potential of automated colony counting and imaging systems for making major advances in cancer research.

“Advancing the frontiers of cancer research: automated colony counting for cancer biologists” is freely available for download now from the Oxford Optronix website:

In the wake of recent landmark discoveries into the molecular and biological changes underlying cancer development, laboratories are attempting to manage “industrial scale” research alongside increasingly restrained budgets from public and private funding bodies. The emergence of three dimensional arrays have only added to these pressures, as manually colony counting these complex in vitro culture systems is proving too labour intensive for laboratories to handle.

The whitepaper forwards the case for employing automated colony counting platforms to reduce the man hours spent on this research, as well as eradicating the error-prone results often encountered in manual counting procedures.

“Advancing the frontiers of cancer research” draws on use findings from Oxford Optronix’s pioneering colony counter, GelCountTM, the first solution of its kind to enable objective colony detection and the only system to be conceived for cancer biologists. The whitepaper explores the issues and challenges of the colony formation assay technique, the rise of 3D arrays and the future of automated counting and image analysis. It also goes on to further explore GelCount’s integrated approach to creating objective detection.

Dr Andy Obeid, CEO of Oxford Optronix, commented: “With the current financial challenges, research laboratories are having to work under increased pressures and restrictions, whilst providing more accurate results and participating in numerous review programmes. This whitepaper reveals how automated systems can provide a cost-effective and more accurate means of undertaking these large scale studies. Adoption of such highly efficient solutions will enable cancer researchers to push past existing barriers to exciting new frontiers.”

More details on GelCountTM can be found here:

--- ends ---

Note to editors:
If you would be interested in scheduling a briefing with Oxford Optronix, please contact Nicky Denovan at nicky[at]evokedset[dot]com.

Press contacts:
Nicky Denovan
EvokedSet PR
nicky [at] evokedset [dot] com

About Oxford Optronix: (
Oxford Optronix is a global pioneer in the design, development and manufacture of sophisticated instrumentation for clinical medicine and life science research.

Founded and managed by academic scientists and with a focus on continuous research and development, Oxford Optronix is committed to making a positive contribution to both patient care and life science research through the design and development of innovative medical devices and scientific instruments for research professionals that set the gold-standard for quality.

Oxford Optronix’s product range includes opto-electronic bio-sensing devices for physiological and tissue vitality monitoring, intelligent imaging systems for automated cell colony counting and contamination-free hypoxia workstations for analysing cell metabolism and function.

With a track record of over 20 years’ success, Oxford Optronix’s team of highly experienced scientists, engineers and technicians design, develop and manufacture its entire product portfolio in-house, ensuring the very highest standards in quality and unparalleled customer support.

Close This Window